Interview with Dexcom’s CEO Terry Gregg

August 11, 2014- Interviewed by Steven E. Greer, MD

Above, in Part 1 of our interview with the CEO of Dexcom, Terry Gregg, we review the business model and products. Mr. Gregg explains how continuous glucose monitoring is safer than finger-stock monitoring.

In Part 2 of the interview, we discuss the bionic pancreas programs underway in academia, and why the Dexcom CGM is the chosen device in most of them.

In Part 3 of the interview, we discuss the financial status of Dexcom. We also go over in more detail the pipeline, and how Apple Computer will be a major partner for Dexcom.

Senator Angus King discusses the slowdown in healthcare costs

July 9, 2014- Interviewed by Steven E. Greer, MD

Senator Angus King from Maine discusses the various forces that are working to keep healthcare cost growth the slowest in decades.

The bionic pancreas data

July 2, 2014- Interviewed by Steven E. Greer, MD

The New England Journal of Medicine recently published the early clinical data on the “bionic pancreas” being developed by engineers at Boston University and medical doctors at Massachusetts General hospital. We interviewed Ed Damiano, PhD, the lead biomedical engineer, and Steven Russell, MD PhD, the lead endocrinologist. In Part 1, they review the clinical data.

The research was funded by the NIH and not a medical device or drug company. The researchers selected the components based on merit. They chose the Dexcom G4 Platinum continuous glucose sensor and a Tandem Diabetes t:slim pump, and used software that ran on a standard Apple iPhone 4S.

In Part 2, the team discusses the details of the pivotal study, that could be concluded by 2016, allowing for an FDA approval by 2017. Industry partners yet to be determined would be involved. However, the final marketed product will not require any particular smartphone to be used by the patient.

 

A modern medical wonder finishes second in the U.S. Open golf tournament

Erik Compton at US OpenJune 15, 2014- By Steven E. Greer, MD

34-year-old Erik Compton finished tied for second in the United States Open golf tournament. That was a good accomplishment by any standard, but it was also a genuine feat of modern medicine and surgery because he is living on his third heart. Read more »

HBO’s John Oliver devotes 16-minutes on the Dr. Oz senate hearing

How did a small academic lab succeed where big medical device companies failed?

July 5, 2014- Interviewed by Steven E. Greer, MD

The New England Journal of Medicine recently published the early clinical data on the “bionic pancreas” being developed by engineers at Boston University and medical doctors at Massachusetts General hospital. We interviewed Ed Damiano, PhD, the lead biomedical engineer, and Steven Russell, MD PhD, the lead endocrinologist.

In Part 3, we asked them how their small lab funded only by the NIH succeeded at developing the bionic pancreas when large companies, such as Roche, Medtronic, Abbott, and JNJ all failed.

 

Senator Angus King discusses his bill to make medical device pricing transparent to the public

July 9, 2014- Interviewed by Steven E. Greer, MD

Senator Angus King from Maine has proposed a a bill that would make the pricing of medical devices more transparent. Currently, hospitals are required to sign confidentiality agreements, and the market is entirely in the dark. If such a law were passed, it would turn the medical device industry on its head.

New therapies for hepatitis C

Interviewed by Steven E. Greer, MD

In Part 1, Sammy Saab, MD, MPH, liver disease and GI doctor from UCLA, discusses the standard of care for hepatitis C, which is 48-weeks of interferon with ribavirin. He then discusses the new protease inhibitor drugs, Incivek and Victrelis, and why their bad side effect profile limited usage despite higher cure rates.

In Part 2, Dr. Saab discusses the data on the new all-oral therapies that do not require the toxic interferon injections, are only 12-weeks of therapy, and have much higher cure rates approaching 100% SVR. He mentions Gilead’s sofosbuvir, the Abbvie cocktail of drugs, and others.

 

Interview with MannKind’s CEO, Al Mann, and CFO, Matt Pfeffer.

October 23, 2013- Interviewed by Steven E. Greer, MD

The Healthcare Channel interviewed the CEO of MannKind, Al Mann, and the CFO, Matt Pfeffer. Topics discussed include the latest clinical trial data on inhaled insulin Afrezza and the cash situation. We also discuss Mr. Mann’s other company, Second Sight, which has a Medicare and FDA-approved bionic eye to treat diseases that damage the nerves in the retina.

Super rapid acting insulin and inhaled insulin

Has the ACA law begun to reduce the uninsured, and at what cost?

July 27, 2014- Interviewed by Steven E. Greer, MD

Ben Sommers, MD PhD, from the Harvard School of Public Health has a new article in the NEJM that attempts to quantify the total number of uninsured people in the country, and map it out temporally to show whether the newly implemented Obamacare law is working as intended.

WordPress Themes